TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10913779
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of NSAIDs (diclofenac sodium salt, fenoprofen calcium salt, ibuprofen, ketoprofen, nabumetone, sulindac)
Study: 10913779
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of antimicrobial drugs (acyclovir, ampicillin, atovaquone, dapsone, enoxacin, ethambutol, lomefloxacin HCl, ofloxacin, pentamidine isethionate, pyrimethamine, sulfamethoxazole, tetracycline HCl, trimethoprim)
Study: 10913779
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of drugs
Study: 8807660
Drug: Fluvoxamine 50
Normalized name: fluvoxamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 50 mg per day for 4 days and 100 mg per day for 8 days
Study: 8807660
Drug: Caffeine 200
Normalized name: caffeine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg orally
Study: 1564678
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive (o.c.)
Study: 31999489
Drug: RT+LP‐L (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT+LP‐L (1.7 mg/kg, low dosage of LP)
Study: 31999489
Drug: RT+LP‐M (5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT+LP‐M (5.2 mg/kg, middle dosage of LP)
Study: 31999489
Drug: RT+LP‐H (10.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT+LP‐H (10.4 mg/kg, high dosage of LP)
Study: 29669604
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg monotherapy)
Study: 23788750
Drug: Lonaprisan 25
Normalized name: Lonaprisan
DrugBank: Lonaprisan (DB16221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lonaprisan 25 mg
Study: 23788750
Drug: Lonaprisan 100
Normalized name: Lonaprisan
DrugBank: Lonaprisan (DB16221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lonaprisan 100 mg
Study: 19730274
Drug: Medication algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication algorithm (n = 14)
Study: 19730274
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psychotherapy and medication (n = 93)
Study: 16769264
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral 30 mg risedronate, oral 1000 mg elemental calcium, and oral 400 IU cholecalciferol
Study: 16769264
Drug: Slowly titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slowly titrated anti-resorptive therapy (subcutaneous calcitonin followed by titrated doses of risedronate)
Study: 15333854
Drug: midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam and 5 mg i.v. hydrocodone
Study: 9425363
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate (ABD; 1 mg/kg.day on days 1‐20, 21‐40 and 61‐80)
Study: 9425363
Drug: Sodium antimony
Normalized name: Sodium antimonyl gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium antimony gluconate (SAG; 20 mg/kg day for 20-day courses with 20-day drug-free intervals)
Study: 8256454
Drug: Anabolic steroid
Normalized name: Anabolic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic steroid therapy
Study: 3541613
Drug: Ritodrine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine plus adjunctive magnesium sulfate
Study: 31665939
Drug: vaginal suppository
Normalized name: Vaginal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal suppository progesterone
Study: 31665939
Drug: tablet aspirin
Normalized name: aspirin Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet aspirin 80 mg
Study: 27777094
Drug: NO3‐rich beetroot
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO3‐rich beetroot juice (BR; 70 mL·day‐1; 6.4 mmol of NO3‐)
Study: 23289279
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) therapy for 10 days during cast immobilization
Study: 23289279
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PEMF therapy)
Study: 18675396
Drug: 10-week device-supported
Normalized name: INCONT DEVICE FEMALE BLADDER SUPPORT SIZE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-week device-supported isolated lumbar extension training, twice a week
Study: 18675396
Drug: Regular physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular physical therapy mainly consisting of exercise therapy and aerobic activities
Study: 10596514
Drug: Cognitive coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive coping skills training added to operant-behavioral treatment (OPCO)
Study: 1725444
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg lacidipine with 160 mg propranolol
Study: 1725444
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg propranolol with 4 mg lacidipine
Study: 1725444
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg lacidipine alone
Study: 1725444
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg propranolol alone
Study: 6617712
Drug: Acetaminophen (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (650 mg single dose)
Study: 21332627
Drug: Saxagliptin 2.5
Normalized name: sAXagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 2.5 mg once daily
Study: 17761914
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen therapy (NBO)
Study: 11022983
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenous MgSO4
Study: 9104904
Drug: Oral propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propafenone (mean dose 663 +/- 99 mg/day)
Study: 9104904
Drug: Oral sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sotalol (mean dose 200 +/- 57 mg/day)
Study: 9104904
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of attack frequency after treatment
Study: 9104904
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of effective response to drugs
Study: 1436603
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg heparan sulfate
Study: 1436603
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg heparan sulfate
Study: 2947099
Drug: Nicergoline (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (standard alpha blocker)
Study: 26634419
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 81 mg daily with 50 mg losartan
Study: 26634419
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 81 mg every 3 days with 50 mg losartan
Study: 20413513
Drug: INCB13739 200
Normalized name: INCB13739
DrugBank: INCB13739 (DB05064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB13739 200 mg
Study: 16037732
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% paraspinal muscle infiltration (30 mL)
Study: 16037732
Drug: Saline paraspinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline paraspinal muscle infiltration (30 mL)
Study: 7138270
Drug: Air pressure
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air pressure splint treatment for 5 consecutive days
Study: 7138270
Drug: Control hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control hand (no treatment)
Study: 31385663
Drug: Severe co-morbidity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe co-morbidity (CIRS-G score grades 3 and 4)
Study: 31385663
Drug: CIRS-G score
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIRS-G score
Study: 27615562
Drug: Atorvastatin 80mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg and ezetimibe 10mg
Study: 27615562
Drug: Routine statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine statin therapy
Study: 19104182
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.125% levobupivacaine (n = 25)
Study: 19104182
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Automated bolus and Continuous infusion)
Study: 16027401
Drug: ABT‐578 (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐578 (200, 400, or 800 microg) as daily intravenous infusions for 14 days
Study: 12381339
Drug: Glutamine-enriched TPN
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched TPN (0.3 g/kg L-alanine-L-glutamine)
Study: 12381339
Drug: Standard TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TPN (1.5 g/kg body weight protein)
Study: 9619493
Drug: Intravenous t-PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous t-PA (tissue plasminogen activator) at a dose of 0.9 mg/kg, administered within 3 hours of symptom onset
Study: 9619493
Drug: Aspirin, heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, heparin, and low‐molecular‐weight heparin products
Study: 3519142
Drug: Bovine lung
Normalized name: defibrotide, bovine lung
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lung heparin
Study: 6997743
Drug: Intestinal-mucosa A
Normalized name: SUS SCROFA INTESTINAL MUCOSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestinal-mucosa A heparin
Study: 6997743
Drug: Intestinal-mucosa O
Normalized name: SUS SCROFA INTESTINAL MUCOSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestinal-mucosa O heparin
Study: 29798795
Drug: Escalated antiarrhythmic
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated antiarrhythmic drug therapy
Study: 24054431
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (0.25 or 0.5 mg/kg/6 hours) added to standard treatment
Study: 21252728
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of equol supplement per day
Study: 1743329
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) cotreatment
Study: 7134840
Drug: Infusion tomography
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion tomography
Study: 30285672
Drug: Transdiagnostic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic group CBT (tCBT) - 12 weekly 2-hour group sessions following a manualized treatment protocol
Study: 30285672
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) for anxiety disorders
Study: 26822537
Drug: Self-management cues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management cues + incentive (free dental treatment)
Study: 24439713
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic putty
Study: 22341824
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including strengthened STI syndromic management, mobile-team outreach for STI screening, presumptive treatment for trichomoniasis, and condom promotion.
Study: 18670365
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of low-dose simvastatin 10 mg with ezetimibe 10 mg
Study: 18670365
Drug: High-dose simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose simvastatin 80 mg
Study: 16002796
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid/d for 3 weeks
Study: 12450886
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids supplementation (3.6 g n-3 fatty acids/d; 2.4 g eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3))
Study: 10605601
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of salicylic acid in ethanol solution
Study: 10605601
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 2 g acetylsalicylic acid
Study: 8557785
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) dosage of 22.8 +/- 10.3 mg/kg/day
Study: 1954079
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg plus Triamterene 50 mg
Study: 1954079
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg plus Terbutaline
Study: 1954079
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg plus Triamterene 50 mg plus Terbutaline
Study: 6751166
Drug: gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil 1200 mg daily for 24 months
Study: 30942150
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (1.5 ml L-1) plus gibberellin
Study: 30942150
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (4.5 ml L-1) under optimum water level
Study: 30942150
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (4.5 ml L-1) plus gibberellin under severe water stress
Study: 17244316
Drug: Chrysalin (TP508)
Normalized name: Chrysalin
DrugBank: Rusalatide acetate (DB11668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chrysalin (TP508) applied topically, twice weekly
Study: 17244316
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) applied topically, twice weekly
Study: 14703471
Drug: IgY solution
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IgY solution
Study: 1424192
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy for 3 months
Study: 23312562
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behavior therapy (8-week program)
Study: 23312562
Drug: Pretreatment Clinician
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment Clinician Administered PTSD Scale severity
Study: 7702230
Drug: Fluvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin with alcohol (40 mg/d + 20 g ethanol diluted to 20% with orange juice)
Study: 7702230
Drug: Fluvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin alone (40 mg/d + orange juice)
Study: 2695556
Drug: Subconjunctival injections
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival injections of clindamycin
Study: 2695556
Drug: Oral pyrimethamine
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pyrimethamine and sulfadiazine (P + S)
Study: 319642
Drug: P/D (Propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: P/D (Propranolol and Digoxin combination)
Study: 30232744
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt containing Lactobacillus acidophilus La5, Bifidobacterium BB12, and Lactobacillus casei DN001 (108 CFU/g each)
Study: 25496176
Drug: Heptavalent pneumococcal
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent pneumococcal conjugate vaccine (PCV), administered to 52 children, monitored for 3 years.
Study: 23175691
Drug: Metformin 1
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1 g in the morning and 500 mg in the evening for 6 months
Study: 12559241
Drug: Daily discrimination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily discrimination training task using an oddball paradigm with cutaneous electrical stimuli for 3 weeks
Study: 8697722
Drug: Exogenous lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous lithium clearance (CLi) with 450 mg lithium
Study: 8697722
Drug: Exogenous lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous lithium clearance (CLi) with 600 mg lithium
Study: 8697722
Drug: Fractional excretion
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional excretion of lithium (FELi) with endogenous lithium
Study: 8697722
Drug: Fractional excretion
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional excretion of lithium (FELi) with 450 mg lithium
Study: 8697722
Drug: Fractional excretion
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional excretion of lithium (FELi) with 600 mg lithium
Study: 6982566
Drug: lonazolac-Ca (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: lonazolac-Ca (200 mg t.i.d.)
Study: 6982566
Drug: diclofenac-Na (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac-Na (50 mg t.i.d.)
Study: 6982566
Drug: indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin (50 mg t.i.d.)
Study: 800385
Drug: 0.05% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% fluocinonide cream
Study: 29735021
Drug: Prednisolone 30
Normalized name: prednisolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 30 mg/day (PRED30; n=12)
Study: 29735021
Drug: Prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 7.5 mg/day (PRED7.5; n=12)
Study: 27723699
Drug: Ademetionin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ademetionin 400 mg 2 times a day for 7 days
Study: 27723699
Drug: Remaxol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaxol 400 ml once a day for 7 days
Study: 20619382
Drug: HCV E1E2
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV E1E2 vaccine adjuvanted with MF59, administered at 3 different dosages on day 0 and weeks 4, 24, and 48.
Study: 20619382
Drug: HCV E1E2
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV E1E2 vaccine adjuvanted with MF59.
Study: 12708964
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) 2x900 mg doses
Study: 10574809
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (deferred treatment)
Study: 6978687
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution (Group A)
Study: 29893003
Drug: ipragliflozin 50
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipragliflozin 50 mg
Study: 19943165
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day ASA
Study: 19943165
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day ASA and 75 mg/day clopidogrel
Study: 19943165
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-platelet medication)
Study: 11812696
Drug: Selective spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective spinal anesthesia (SSA) with lidocaine 10 mg + sufentanil 10 microg
Study: 8934059
Drug: Triphasic OC
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic OC pill containing 35 mg ethinyl estradiol (EE) and 50 mg desogestrel (DSG) in the first seven tablets; 30 mg EE and 100 mg DSG in tablets 8 to 14, and 30 mg EE and 150 mg DSG in tablets 15 to 21
Study: 8934059
Drug: OC pills
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC pills containing 20 mg EE plus 150 mg DSG (15 patients) or 75 mg of gestodene (14 patients)
Study: 6358486
Drug: Psychological techniques
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological techniques for reducing dependence on hypnotics
Study: 6358486
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (users who did not receive psychological treatment)
Study: 25383780
Drug: Direct access
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct access to low-dose computed tomography (LDCT) combined with a Continuing Medical Education (CME) meeting on lung cancer diagnosis
Study: 21967845
Drug: EPA-DHA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-DHA (400 mg/d)
Study: 21967845
Drug: ALA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA (2 g/d)
Study: 21309493
Drug: Flurbiprofen 100
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 100 mg orally 1 hour prior to HSG
Study: 17681958
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa weight-based dosing (0.75 mcg/kg every 2 weeks for 26 weeks)
Study: 17681958
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa fixed dosing (50 mcg every 2 weeks for 26 weeks)